IRIS Institutional Research Information System - OPENBS Open Archive UniBS

RUSSO, DOMENICO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 32.286
AS - Asia 16.182
EU - Europa 12.116
SA - Sud America 3.568
Continente sconosciuto - Info sul continente non disponibili 1.127
AF - Africa 415
OC - Oceania 63
Totale 65.757
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 31.485
SG - Singapore 5.493
CN - Cina 5.232
BR - Brasile 2.911
UA - Ucraina 2.783
IT - Italia 2.204
HK - Hong Kong 1.833
DE - Germania 1.618
PL - Polonia 1.096
VN - Vietnam 1.082
FI - Finlandia 949
FR - Francia 787
GB - Regno Unito 682
BD - Bangladesh 628
TR - Turchia 595
RU - Federazione Russa 563
IE - Irlanda 506
IN - India 458
CA - Canada 383
SE - Svezia 310
AR - Argentina 234
MX - Messico 160
IQ - Iraq 132
ZA - Sudafrica 124
EC - Ecuador 111
ID - Indonesia 111
JP - Giappone 105
NL - Olanda 101
CO - Colombia 100
ES - Italia 92
CZ - Repubblica Ceca 78
AT - Austria 72
VE - Venezuela 68
SA - Arabia Saudita 62
AU - Australia 60
BE - Belgio 57
UZ - Uzbekistan 56
PK - Pakistan 51
MA - Marocco 49
JM - Giamaica 43
EG - Egitto 40
PY - Paraguay 38
CL - Cile 35
MU - Mauritius 35
PE - Perù 34
CR - Costa Rica 31
KE - Kenya 30
NG - Nigeria 30
AE - Emirati Arabi Uniti 29
JO - Giordania 29
TT - Trinidad e Tobago 28
IL - Israele 27
PH - Filippine 27
AZ - Azerbaigian 26
EU - Europa 26
HN - Honduras 25
DZ - Algeria 22
NI - Nicaragua 22
TN - Tunisia 22
UY - Uruguay 22
CH - Svizzera 21
NP - Nepal 21
LT - Lituania 20
GT - Guatemala 19
MY - Malesia 19
SV - El Salvador 19
DK - Danimarca 18
KR - Corea 18
OM - Oman 18
ET - Etiopia 17
TH - Thailandia 17
KZ - Kazakistan 16
PA - Panama 16
RO - Romania 16
EE - Estonia 15
GR - Grecia 15
IR - Iran 15
SN - Senegal 15
DO - Repubblica Dominicana 14
HU - Ungheria 14
KG - Kirghizistan 14
BO - Bolivia 12
PT - Portogallo 12
AL - Albania 11
LB - Libano 11
BA - Bosnia-Erzegovina 10
MD - Moldavia 10
PS - Palestinian Territory 10
BG - Bulgaria 9
PR - Porto Rico 9
SK - Slovacchia (Repubblica Slovacca) 9
BB - Barbados 8
CW - ???statistics.table.value.countryCode.CW??? 7
LK - Sri Lanka 7
LV - Lettonia 7
AM - Armenia 6
GP - Guadalupe 6
HR - Croazia 6
RS - Serbia 6
AO - Angola 5
Totale 64.560
Salva come PNG Salva come JPEG
Città #
Ashburn 3.241
Singapore 2.817
Woodbridge 2.462
Fairfield 2.432
Jacksonville 1.979
Hong Kong 1.829
Houston 1.807
San Jose 1.769
Ann Arbor 1.356
Council Bluffs 1.176
Cambridge 1.085
Warsaw 1.076
Wilmington 976
The Dalles 975
Seattle 967
Princeton 939
Beijing 852
Chandler 801
New York 783
Nanjing 657
Los Angeles 540
Dublin 493
Helsinki 489
Lauterbourg 479
Istanbul 438
Dallas 433
Columbus 379
Ho Chi Minh City 360
Brescia 337
Munich 334
Des Moines 326
São Paulo 315
Milan 292
Nanchang 267
Buffalo 234
Shanghai 232
Hanoi 231
Santa Clara 220
Moscow 192
Redondo Beach 177
San Diego 174
Changsha 172
San Francisco 170
Shenyang 166
Chicago 155
Dearborn 148
Tianjin 143
Jinan 133
Hebei 129
Rome 127
Orem 124
Boardman 118
Toronto 117
London 110
Jiaxing 109
Turku 108
Phoenix 106
Brooklyn 100
Hangzhou 96
Tokyo 92
Atlanta 88
Denver 84
Verona 83
Kunming 76
Rio de Janeiro 73
Montreal 72
Nuremberg 72
Brasília 70
Frankfurt am Main 69
Chennai 66
Guangzhou 66
Kocaeli 65
Johannesburg 60
Brno 59
Zhengzhou 58
Belo Horizonte 57
Boston 56
Brussels 56
Curitiba 54
Pune 54
North Bergen 53
Ningbo 49
Romola 47
Tashkent 47
Baghdad 45
Manchester 45
Stockholm 45
Lanzhou 44
Mexico City 44
Charlotte 43
Haiphong 43
Poplar 41
Turin 41
Guayaquil 37
Mumbai 37
Norwalk 37
Dong Ket 36
Da Nang 35
Naples 35
Salvador 35
Totale 41.521
Salva come PNG Salva come JPEG
Nome #
Mesenchymal stromal cells (MSCs) induce ex vivo proliferation and erythroid commitment of cord blood haematopoietic stem cells (CB-CD34+ cells) 336
BACTERIAL BLOOD STREAM INFECTIONS NEGATIVELY IMPACT ON OUTCOME OF PATIENTS TREATED WITH ALLOGENEIC STEM CELL TRANSPLANTATION: 6 YEARS SINGLE-CENTRE EXPERIENCE 302
Postremission sequential monitoring of minimal residual disease by WT1 Q-PCR and multiparametric flow cytometry assessment predicts relapse and may help to address risk-adapted therapy in acute myeloid leukemia patients 299
Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain 292
A standardized flow cytometry network study for the assessment of circulating endothelial cell physiological ranges 285
Circulating endothelial cell count: a reliable marker of endothelial damage in patients undergoing hematopoietic stem cell transplantation 281
“Variant-specific discrepancy when quantitating BCR-ABL1 e13a2 and e14a2 transcripts using the Europe Against Cancer qPCR assay.” Is dPCR the key? 265
Zebrafish disease models in hematology: Highlights on biological and translational impact 251
Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia. 249
Do chromosomal abnormalities show up during mesenchymal stromal cell expansion? 246
3D gelatin-chitosan hybrid hydrogels combined with human platelet lysate highly support human mesenchymal stem cell proliferation and osteogenic differentiation 228
A specific Toll-like receptor profile on T lymphocytes and values of monocytes correlate with bacterial, fungal, and cytomegalovirus infections in the early period of allogeneic stem cell transplantation 220
Feasibility of tumor‑derived exosome enrichment in the onco‑hematology leukemic model of chronic myeloid leukemia 215
Betaherpesvirus Reactivation and Toll-Like Receptor Expression After Allogeneic Stem Cell Transplantation. 213
Comparative study on ATG-thymoglobulin versus ATG-fresenius for the graft-versus-host disease (GVHD) prophylaxis in allogeneic stem cell transplantation from matched unrelated donor: a single-centre experience over the contemporary years 210
Bloodstream infections in haematological cancer patients colonized by multidrug-resistant bacteria 207
EXPRESSION OF TOLL-LIKE RECEPTORS ON PERIPHERAL BLOOD CELLS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: ONGOING RESULTS OF A PROSPECTIVE STUDY. 205
Evaluation of Circulating Endothelial Cells as Direct Marker of Endothelial Damage in Allo-Transplant Recipients at High Risk of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome 204
Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease 196
Counting circulating endothelial cells in allo-HSCT: an ad hoc designed polychromatic flowcytometry-based panel versus the CellSearch System 194
Rational Design and Development of Anisotropic and Mechanically Strong Gelatin-Based Stress Relaxing Hydrogels for Osteogenic/Chondrogenic Differentiation 194
Targeting HRASV12G Expression to the Zebrafish Early Hemogenic Progenitors Induces a Myeloproliferative Disorder by Repressing the Notch Pathway. 194
A first update on mapping the human genetic architecture of COVID-19 192
Profile of Toll-Like Receptors on Peripheral Blood Cells in Relation to Acute Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation 191
A Gene Panel NGS-Based Strategy for Genomic Characterization of Acute Myeloid Leukemias (AMLs) 190
Comparative Somatic Mutational Profiling of CD34+ Hematopoietic Precursors (HSC) and Circulating Endothelial Cells (CEC) in Patients with Primary Myelofibrosis (PMF) 189
Venetoclax plus decitabine as a bridge to allogeneic haematopoietic stem-cell transplantation in older patients with acute myeloid leukaemia (VEN-DEC GITMO): final report of a multicentre, single-arm, phase 2 trial 188
Advances in CMV Management: A Single Center Real-Life Experience 186
Acute graft-versus-host disease and expression of Toll-like receptors on peripheral blood cells after allogeneic stem cell transplantation 184
Expression of Toll-Like Receptors on Peripheral Blood Cells After Allogeneic Stem Cell Transplantation: Results of a Prospective Study. 183
TARGETING HRASV12G EXPRESSION TO THE ZEBRAFISH EARLY HEMOGENIC PROGENITORS INDUCES A MYELOPROLIFERATIVE DISORDER BY REPRESSING THE NOTCH PATHWAY. 182
Splenomegaly in patients with primary or secondary myelofibrosis who are candidates for allogeneic hematopoietic cell transplantation: a Position Paper on behalf of the Chronic Malignancies Working Party of the EBMT 181
Intermittent Imatinib (INTERIM) Treatment of Patients with Ph+ Chronic Myeloid Leukemia in Complete Cytogenetic Response: Cytogenetic and Molecular Data At One Year. 180
In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants 177
Central Venous Catheter-Related Bloodstream Infection Caused by Brevibacterium casei in a Hematology Patient 177
Multidimensional Geriatric Assessment for Elderly Patients (≥60 years) Submitted for Allogeneic Stem Cell Transplantation. a French (Paris) - Italian (Brescia) 10-Years Experience on 228 Patients 177
Assessment of BCR-ABL1 Transcript Levels By Digital PCR (dPCR) in CML Patients who Achieved a Deep Molecular Response (DMR: MR4.0, MR4.5 And MR5.0) with Tkis May Improve the Detection of Minimal Residual Disease (MRD) and the Selection of Patients for Treatment Free Remission (TFR) 177
SIRPB1 Is a Strong Predictor Biomarker of Response to 5-Azacitidine Therapy in MDS and AML Patients 175
Development of BCR-ABL1 Transgenic Zebrafish Model Reproducing Chronic Myeloid Leukemia (CML) Like-Disease and Providing a New Insight into CML Mechanisms 175
CMV MANAGEMENT WITH SPECIFIC IMMUNOGLOBULINS: A MULTICENTRIC RETROSPECTIVE ANALYSIS ON 92 ALLOTRANSPLANTED PATIENTS 174
Procoagulant cellular activity and disseminated intravascular coagulation in acute non-lymphoid leukaemia. 172
Clinical Care of Hematological Patients in a Bone Marrow Transplant Unit: Do Human Resources Influence Infection Incidence? 172
High risk-myelodysplastic syndrome following CAR T-cell therapy in a patient with relapsed diffuse large B cell lymphoma: A case report and literature review 171
Chitosan-Hydrogel Polymeric Scaffold Acts as an Independent Primary Inducer of Osteogenic Differentiation in Human Mesenchymal Stromal Cells 170
Different In Vitro Models of Chronic Myeloid Leukemia Show Different Characteristics: Biological Replicates Are Not Biologically Equivalent 169
A prospective comparison of alpha-IFN and conventional chemotherapy in Ph+ chronic myeloid leukemia. Clinical and cytogenetic results at 2 years in 322 patients 169
A simple prognostic scoring system for newly diagnosed cytogenetically normal acute myeloid leukemia: retrospective analysis of 530 patients. 169
Fungemia in hematological malignancies: SEIFEM-2015 survey 168
Development of a Preclinical Double Model of Mandibular Irradiated Bone and Osteoradionecrosis in New Zealand Rabbits 167
Peripheral Blood WT1 Expression Predicts Relapse in AML Patients Undergoing Allogeneic Stem Cell Transplantation. 167
3D-MAPPING OF MESENCHYMAL STEM CELLS GROWTH ON BIOENGINEERED SCAFFOLDS FOR MAXILLOFACIAL SKELETON REGENERATION: A PRECLINICAL, IN VITRO STUDY 167
"Real-life' analysis of the role of antifungal prophylaxis in preventing invasive aspergillosis in AML patients undergoing consolidation therapy: Sorveglianza Epidemiologica Infezioni nelle Emopatie (SEIFEM) 2016 study 166
Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation 166
Bioengineered scaffolding for mandibular reconstruction: a preclinical, xenograft animal study 165
5-azacitidine five days/monthly schedule in symptomatic low-risk (IPSS: 0-1) myelodisplastic (MDS) patients. clinical and biological effects. 164
Development of a cell culture model based on biocompatible polymeric scaffolds engineered with human Mesenchymal Stromal Cells (MSCs) for cartilage and bone regenerative therapy 164
Identification of a Novel Mutation Predisposing to Familial AML and MDS Syndrome By a NGS Approach 164
Screening of Bcr-Abl transcripts in Philadelphia negative essential thrombocythemia. 163
Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto Acute Leukemia Working Party (GIMEMA AL WP) 163
Allogeneic transplantation for patient with myelodisplastic sindromes: a single centre experience 163
Central nervous system angiitis in Hodgkin's disease. 162
MULTI-GENOTYPING OF MINOR HISTOCOMPATIBILITY ANTIGENS (MHAGS) IN ALLOGENEIC STEM CELL TRANSPLANTATION AND THEIR ROLE IN DETERMINING GRAFT VERSUS HOST DISEASE (GVHD) AND GRAFT VERSUS LEUKEMIA (GVL) EFFECT. 162
Liposomal doxorubicin for the treatment of iatrogenic kaposi sarcoma following hematopoietic stem cell transplantation 162
Assessment of Liver Damage with Transient Hepatic Elastography (FIBROSCAN) in patients with chronic Graft-Versus-Host Disease. 161
Imatinib mesylate in the treatment of c-kit-positive acute myeloid leukemia: is this the real target? 161
Parameters of Protein Metabolism and Thyroid Function As Predictors in a Scoring System for Acute and Chronic Graft-Versus-Host Disease 161
Incidence, Risk Factors and Outcome of Pre-engraftment Gram-Negative Bacteremia After Allogeneic and Autologous Hematopoietic Stem Cell Transplantation: An Italian Prospective Multicenter Survey. 161
Is the New Tci Score Sufficient to Categorize the Intensity of Conditioning? a Single-Centre Study 160
Single Cell Analysis of Circulating Endothelial Cells in Allogeneic Hematopoietic Stem Cell Transplant; To Whom Do They Belong: Host or Donor? 160
Targeting oncogene expression to endothelial cells induces proliferation of the myelo-erythroid lineage by repressing the notch pathway. 159
Managing chronic myeloid leukaemia in the elderly with intermittent imatinib treatment 159
RT-qPCR versus Digital PCR: How Do They Impact Differently on Clinical Management of Chronic Myeloid Leukemia Patients? 159
P-glycoprotein (PGP) and lung resistance-related protein (LRP) expression and function in leukaemic blast cells. 158
Fludarabine-based induction therapy does not overcome the negative effect of ABCG2 (BCRP) over-expression in adult acute myeloid leukemia patients. 158
Bone marrow CD34+ molecular chimerism as an early predictor of relapse after allogeneic stem cell transplantation in patients with acute myeloid leukemia 157
PARAMETERS OF PROTEIN METABOLISM AND THYROID FUNCTION AS PREDICTORS OF A SCORING SYSTEM FOR ACUTE AND CHRONIC GRAFT-VERSUS-HOST DISEASE 157
Bone Marrow Stroma and Vascular Contributions to Myeloma Bone Homing 157
Baseline factors associated with response to ruxolitinib: An independent study on 408 patients with myelofibrosis 157
Pneumocystis carinii pneumonia in patients with malignant haematological diseases: 10 years’ experience of infection in GIMEMA centres. 157
Antilymphocyte globulin for prevention of chronic graft-versus-host disease 156
CT-290: Clinical Frailty Scale as a Novel Tool to Evaluate Patients’ Eligibility for Allogeneic Stem Cell Transplant: A Single-Center Experience on 234 Patients >50 Years Old 156
TOLL-LIKE RECEPTORS ON PERIPHERAL BLOOD CELLS AND ACUTE GRAFT-VERSUS-HOST DISEASE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: RESULTS OF A PROSPECTIVE STUDY 155
DIGITAL PCR IN PH plus CHRONIC MYELOID LEUKEMIA PATIENTS FOR RECOGNITION OF "STABLE" DEEP MOLECULAR RESPONSE AND IDENTIFICATION OF BEST CANDIDATES TO TKI DISCONTINUATION 155
Concomitant ABCG2 overexpression and FLT3-ITD mutation identify a subset of acute myeloid leukemia patients at high risk of relapse 154
First Interim Report of the Italian Multicentric Phase-III Randomized Study to Optimize TKIs Multiple Approaches - (OPTkIMA) in Elderly Patients (older than 60 years) with Ph+ Chronic Myeloid Leukemia (CML) and MR3.0/ MR4.0 Stable Molecular Response 154
Impedance-based monitoring of mesenchymal stromal cell three-dimensional proliferation using aerosol jet printed sensors: A tissue engineering application 154
Hyperactive Akt1 Signaling Increases Tumor Progression and DNA Repair in Embryonal Rhabdomyosarcoma RD Line and Confers Susceptibility to Glycolysis and Mevalonate Pathway Inhibitors 152
SHP-1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome-positive cells derived from patients with chronic myeloid leukemia. 151
Urinary Protein Levels in Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Multiple Myeloma (SMM) Predict Severe Disease Related Complications at Myeloma Progression 151
Case-control study of multidrug resistance phenotype and response to induction treatment including or not fludarabine in newly diagnosed acute myeloid leukaemia patients. 150
Procoagulant cellular activity and disseminated intravascular coagulation in acute non-lymphoid leukaemia 150
Ibrutinib as a salvage therapy after allogeneic HCT for chronic lymphocytic leukemia 150
Digital PCR (Dpcr) a Step Forward to Detection and Quantification of Minimal Residual Disease (MRD) in Ph+/BCR-ABL1 Chronic Myeloid Leukemia (CML) 150
Multidimensional geriatric assessment for elderly hematological patients (≥60 years) submitted to allogeneic stem cell transplantation. A French-Italian 10-year experience on 228 patients 150
A NEW PROMISING APPROACH TO PERFORM HLA TYPING IN A QUICKLY, SIMPLE AND ACCURATE WAY: THE PYROSEQUENCING 149
ANTI-CMV Immunoglobulins in Association with ANTI-CMV Drugs in Patients with Hematological Malignancies Submitted to Allogeneic STEM CELL Transplantation: A MULTI-Center Retrospective Experience 149
Advances in the treatment of monoclonal gammapathies: the emerging role of targeted therapy in plasma cell dyscrasias. 148
Comparative Study on Fresenius-ATG Versus Thymoglobuline-ATG for the Graft Versus Host Disease (GVHD) Prophylaxis in Allogeneic Stem Cell Transplantation from Matched Unrelated Donor: A Single Center Experience on 76 Patients 148
Laparoscopic splenectomy in the management of hematological diseases 147
TRIDIMENSIONAL BIOACTIVE POROUS BODY FOR BONE TISSUE REGENERATION AND PROCESS FOR ITS PREPARATION 147
Totale 18.107
Salva come PNG Salva come JPEG
Categoria #
all - tutte 328.577
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 328.577
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.682 0 0 0 244 107 233 171 266 198 441 274 748
2022/20232.713 571 96 68 211 213 725 13 229 318 35 105 129
2023/20243.469 162 75 233 168 151 598 159 140 953 41 64 725
2024/20258.648 76 93 95 972 922 700 731 274 1.097 685 1.684 1.319
2025/202619.293 1.558 2.529 1.591 2.962 1.579 1.359 2.598 871 1.237 1.676 808 525
2026/20276.295 906 959 1.573 2.857 0 0 0 0 0 0 0 0
Totale 65.757